Exanta (ximelagatran) is an oral direct thrombin inhibitor developed by AstraZeneca. It is indicated for the prevention and treatment of venous thromboembolism (VTE) and potentially for the prevention of stroke in patients with atrial fibrillation. (Source: ABPI)
-
Exanta (ximelagatran) is an oral direct thrombin inhibitor developed by... -
VTE encompasses both DVT and PE and is the third most common cardiovascular... -
Drawbacks associated with the routine use of Warfarin for anti-coagulation...
